scholarly journals Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Mamatha Bhat ◽  
Kathleen C. Rollet-Kurhajec ◽  
Aparna Bhat ◽  
Amanda Farag ◽  
Marc Deschenes ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Transplant ◽  
Hcv Infection ◽  
Serum Biomarker ◽  
Advanced Fibrosis ◽  
Advanced Liver Fibrosis ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Liver Transplant Recipients

Background and Aims. Serum fibrosis biomarkers have shown good accuracy in the liver transplant (LT) population. We employed a simple serum biomarker to elucidate incidence and predictors of advanced fibrosis after LT over a long follow-up period.Methods. We included 440 consecutive patients who underwent LT between 1991 and 2013. Advanced liver fibrosis was defined as FIB-4 > 3.25 beyond 12 months after LT.Results. Over 2030.5 person-years (PY) of follow-up, 189 (43%) developed FIB-4 > 3.25, accounting for an incidence of 9.3/100 PY (95% confidence interval [CI], 8.1–10.7). Advanced fibrosis was predicted by chronic HCV infection (adjusted hazard ratio (aHR) = 3.96, 95% CI 2.92–5.36,p< 0.001), hypoalbuminemia (aHR = 2.31, 95% CI 1.72–3.09;p< 0.001), and hyponatremia (aHR = 1.48, 95% CI 1.09–2.01;p= 0.01). LT recipients with more than 1 predictor had a higher incidence of advanced fibrosis, the highest being when all 3 predictors coexisted (log-rank:p< 0.001).Conclusions. Chronic HCV infection, hypoalbuminemia, and hyponatremia predict progression to advanced liver fibrosis following LT. Patients with these risk factors should be serially monitored using noninvasive fibrosis biomarkers and prioritized for interventions.

scholarly journals Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7666 ◽  
Author(s):  
Kessarin Thanapirom ◽  
Sirinporn Suksawatamnuay ◽  
Wattana Sukeepaisarnjaroen ◽  
Pisit Tangkijvanich ◽  
Panarat Thaimai ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Poor Response ◽  
Pegylated Interferon ◽  
Hcv Infection ◽  
Hcv Rna ◽  
Advanced Liver Fibrosis ◽  
Chronic Hcv Infection ◽  
Pre Treatment ◽  
Hcv Genotype 1 ◽  
Chronic Hcv

Vitamin D receptor (VDR) modulates host immune responses to infections such as hepatitis C virus (HCV) infection, including interferon signaling. This study aimed to investigate the associations of VDR polymorphisms with advanced liver fibrosis and response to pegylated interferon (PEG-IFN)-based therapy in patients with chronic HCV infection. In total, 554 Thai patients with chronic HCV infection treated with a PEG-IFN-based regimen were enrolled. Six single-nucleotide polymorphisms (SNPs) were genotyped: the IL28B C > T (rs12979860) SNP and five VDR SNPs, comprising FokI T > C (rs2228570), BsmI C > T (rs1544410), Tru9I G > A (rs757343), ApaI C > A (rs7975232), and TaqI A > G (rs731236). In total, 334 patients (60.3%) achieved sustained virological response (SVR), and 255 patients (46%) were infected with HCV genotype 1. The bAt (CCA) haplotype, consisting of the BsmI rs1544410 C, ApaI rs7975232 C, and TaqI rs731236 A alleles, was associated with poor response (in terms of lack of an SVR) to PEG-IFN-based therapy. The IL28B rs12979860 CT/TT genotypes (OR = 3.44, 95% CI [2.12–5.58], p < 0.001), bAt haplotype (OR = 2.02, 95% CI [1.04–3.91], p = 0.03), pre-treatment serum HCV RNA (logIU/mL; OR = 1.73, 95% CI [1.31–2.28], p < 0.001), advanced liver fibrosis (OR = 1.68, 95% CI [1.10–2.58], p = 0.02), and HCV genotype 1 (OR = 1.59, 95% CI [1.07–2.37], p = 0.02) independently predicted poor response. Patients with the bAt haplotype were more likely to have poor response compared to patients with other haplotypes (41.4% vs 21.9%, p = 0.03). The FokI rs2228570 TT/TC genotypes (OR = 1.63, 95% CI [1.06–2.51], p = 0.03) and age ≥55 years (OR = 2.25; 95% CI [1.54–3.32], p < 0.001) were independently associated with advanced liver fibrosis, assessed based on FIB-4 score >3.25. VDR polymorphisms were not associated with pre-treatment serum HCV RNA. In Thai patients with chronic HCV infection, the bAt haplotype is associated with poor response to PEG-IFN-based therapy, and the FokI rs2228570 TT/TC genotypes are risk factors for advanced liver fibrosis.

scholarly journals Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

2017 ◽  
Vol 38 (5) ◽  
pp. 821-833 ◽  
Author(s):  
K. Rajender Reddy ◽  
Stanislas Pol ◽  
Paul J. Thuluvath ◽  
Hiromitsu Kumada ◽  
Joji Toyota ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Hcv Infection ◽  
Long Term Follow Up ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

Predictors of Liver Fibrosis in Patients with Chronic HCV Infection

2012 ◽  
Vol 32 (6) ◽  
pp. 1522-1529 ◽  
Author(s):  
Bahadır CEYLAN ◽  
Cem YARDIMCI ◽  
Muzaffer FİNCANCI ◽  
Ümit TÖZALGAN ◽  
Gülhan EREN ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Chronic Hcv Infection ◽  
Chronic Hcv

scholarly journals Non-invasive methods for the diagnosis of liver fibrosis in chronic HCV infection

2019 ◽  
Vol 17 (8) ◽  
pp. 44-47
Author(s):  
A. I. Fazulzyanova ◽  
◽  
S. V. Tkacheva ◽  
A. K. Khusainova ◽  
N. F. Gayfutdinov ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hcv Infection ◽  
Non Invasive ◽  
Chronic Hcv Infection ◽  
Chronic Hcv
Sign in / Sign up

Export Citation Format

Share Document